Cost-effectiveness Analysis with Influence Diagrams

被引:12
作者
Arias, M. [1 ]
Diez, F. J. [1 ]
机构
[1] UNED, Dept Artificial Intelligence, Madrid 28040, Spain
关键词
Cost-benefit analysis; cost-effectiveness analysis; decision trees; influence diagrams; INFERENCE; HEALTH;
D O I
10.3414/ME13-01-0121
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Background: Cost-effectiveness analysis (CEA) is used increasingly in medicine to determine whether the health benefit of an intervention is worth the economic cost. Decision trees, the standard decision modeling technique for non-temporal domains, can only perform CEA for very small problems. Objective: To develop a method for CEA in problems involving several dozen variables. Methods: We explain how to build influence diagrams (IDs) that explicitly represent cost and effectiveness. We propose an algorithm for evaluating cost-effectiveness IDs directly, i.e., without expanding an equivalent decision tree. Results: The evaluation of an ID returns a set of intervals for the willingness to pay separated by cost-effectiveness thresholds and, for each interval, the cost, the effectiveness, and the optimal intervention. The algorithm that evaluates the ID directly is in general much more efficient than the brute-force method, which is in turn more efficient than the expansion of an equivalent decision tree. Using OpenMarkov, an open-source software tool that implements this algorithm, we have been able to perform CEAs on several IDs whose equivalent decision trees contain millions of branches. Conclusion: IDs can perform CEA on large problems that cannot be analyzed with decision trees.
引用
收藏
页码:353 / 358
页数:6
相关论文
共 50 条
  • [31] Cost-effectiveness analysis and capital costs
    Karlsson, G
    Johannesson, M
    SOCIAL SCIENCE & MEDICINE, 1998, 46 (09) : 1183 - 1191
  • [32] Longevity bias in cost-effectiveness analysis
    Liu, Liqun
    Rettenmaier, Andrew J.
    Saving, Thomas R.
    HEALTH ECONOMICS, 2008, 17 (04) : 523 - 534
  • [33] Ethical issues in cost-effectiveness analysis
    Pinkerton, SD
    Johnson-Masotti, AP
    Derse, A
    Layde, PM
    EVALUATION AND PROGRAM PLANNING, 2002, 25 (01) : 71 - 83
  • [34] Indirect costs and cost-effectiveness analysis
    Ernst, Richard
    VALUE IN HEALTH, 2006, 9 (04) : 253 - 261
  • [35] The Next Chapter in Cost-effectiveness Analysis
    Roberts, Mark S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (10): : 1049 - 1050
  • [36] POLSSS: overview and cost-effectiveness analysis
    Walker, WE
    SAFETY SCIENCE, 2000, 35 (1-3) : 105 - 121
  • [37] ON THE DECISION RULES OF COST-EFFECTIVENESS ANALYSIS
    JOHANNESSON, M
    WEINSTEIN, MC
    JOURNAL OF HEALTH ECONOMICS, 1993, 12 (04) : 459 - 467
  • [38] Cost-effectiveness analysis for heterogeneous samples
    Moreno, E.
    Giron, F. J.
    Vazquez-Polo, F. J.
    EUROPEAN JOURNAL OF OPERATIONAL RESEARCH, 2016, 254 (01) : 127 - 137
  • [39] Cost-effectiveness analysis: role and implications
    Marsden, G.
    Wonderling, D.
    PHLEBOLOGY, 2013, 28 : 135 - 140
  • [40] Cost-effectiveness analysis in infectious diseases
    Paul, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (12) : 1705 - 1706